Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Pharma-Bio Serv, Inc.

pharma-bioserv.com
Filed: Mar 17, 2026CIK: 0001304161Manufacturing
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Pharma-Bio Serv, Inc. announced Q1 2026 financial results for the quarter ended January 31, 2026 via press release on March 17, 2026. This routine earnings announcement provides shareholders and analysts with operational performance metrics to assess the company's financial health.

Key Takeaways

Company issued Q1 2026 earnings announcement covering the quarter ended January 31, 2026

Filing is a standard 8-K Item 2.02 disclosure for results of operations and financial condition

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMar 17, 2026
Item2.02
CategoryFinancial Results
CIK0001304161
Accession #0001304161
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings